Yi Q, Eriksson I, He W, Holm G, Mellstedt H, Osterborg A
Department of Medicine, Karolinska Hospital, Stockholm, Sweden.
Br J Haematol. 1997 Feb;96(2):338-45. doi: 10.1046/j.1365-2141.1997.d01-2021.x.
Tumour-specific CD4+ T helper (Th) and CD8+ T cytotoxic (Tc) cells may participate in the control and eradication of tumour cells. In the present study, idiotype-specific stimulation of CD4+ and CD8+ blood T cells from patients with monoclonal gammopathy of undetermined significance and patients with untreated multiple myeloma stage I was examined. Activation was measured in the CD4+ and CD8+ subsets enriched by magnetic microbeads as the incorporation of 3H-thymidine and the secretion of interferon (IFN)-gamma, interleukin (IL)-2 and IL-4 by single cells using the enzyme-linked immunospot assay. Idiotype-specific T cells were found in four of seven patients. Stimulation was mainly confined to the CD4+ subset in three of the four responding patients. This type of response was major histocompatibility complex (MHC) class II restricted as it could be inhibited by monoclonal antibodies against MHC class II (HLA-DR), but not against class I (HLA-ABC) molecules. Idiotype-specific CD8+ T cells were also demonstrated in these patients although at a lower frequency. One patient showed a strong and dominating activation of CD8+ T cells which could be blocked by antibodies against HLA-ABC but not against HLA-DR. Idiotype-specific CD4+ or CD8+ T cells were mainly of the type-1 subsets as judged by their secretion of IFN-gamma and IL-2. Thus, this study provides evidence for the presence of idiotype-specific and MHC-restricted CD4+ and CD8+ T cells of the type-1 subsets in patients with monoclonal gammopathies. Such T cells with the potential to control the growth of tumour B cells may be a suitable target for immunotherapeutic interventions in patients.
肿瘤特异性CD4 +辅助性T细胞(Th)和CD8 +细胞毒性T细胞(Tc)可能参与肿瘤细胞的控制和清除。在本研究中,检测了意义未明的单克隆丙种球蛋白病患者和未经治疗的I期多发性骨髓瘤患者的CD4 +和CD8 +血液T细胞的独特型特异性刺激。通过磁珠富集的CD4 +和CD8 +亚群中的激活情况,以3H-胸腺嘧啶核苷的掺入量以及使用酶联免疫斑点法检测单细胞分泌的干扰素(IFN)-γ、白细胞介素(IL)-2和IL-4来衡量。在7例患者中有4例发现了独特型特异性T细胞。在4例有反应的患者中,有3例刺激主要局限于CD4 +亚群。这种反应受主要组织相容性复合体(MHC)II类限制,因为它可被抗MHC II类(HLA-DR)单克隆抗体抑制,但不能被抗I类(HLA-ABC)分子的抗体抑制。这些患者中也证实存在独特型特异性CD8 + T细胞,尽管频率较低。1例患者表现出CD8 + T细胞的强烈且占主导地位的激活,这可被抗HLA-ABC抗体阻断,但不能被抗HLA-DR抗体阻断。根据其IFN-γ和IL-2的分泌情况判断,独特型特异性CD4 +或CD8 + T细胞主要属于1型亚群。因此,本研究为单克隆丙种球蛋白病患者中存在独特型特异性且受MHC限制的1型亚群CD4 +和CD8 + T细胞提供了证据。这种有潜力控制肿瘤B细胞生长的T细胞可能是患者免疫治疗干预的合适靶点。